HCV treatment initiation in the era of universal direct acting antiviral coverage – Improvements in access and persistent barriers

Abbott, 2021, Welcomeness for people with substance use disorders to general practice: A qualitative study, Family Practice, 39, 257, 10.1093/fampra/cmab151 Akiyama, 2021, Hepatitis C elimination among people incarcerated in prisons: Challenges and recommendations for action within a health systems framework, The Lancet Gastroenterology & Hepatology, 6, 391, 10.1016/S2468-1253(20)30365-4 Amoako, 2021, Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis, International Journal of Drug Policy, 96, 10.1016/j.drugpo.2021.103247 Arora, 2011, Outcomes of treatment for hepatitis C virus infection by primary care providers, New England Journal of Medicine, 364, 2199, 10.1056/NEJMoa1009370 Artenie, 2014, Role of primary care providers in hepatitis C prevention and care: One step away from evidence-based practice, Canadian Family Physician, 60, 881 Artenie, 2021, Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection, International Journal of Drug Policy, 96, 10.1016/j.drugpo.2021.103419 Artenie, 2015, Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement, Journal of Viral Hepatitis, 22, 792, 10.1111/jvh.12393 Asher, 2016, Clinicians' views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs, Substance Use & Misuse, 51, 1218, 10.3109/10826084.2016.1161054 Assoumou, 2020, Cost-effectiveness and budgetary impact of hepatitis C virus testing, treatment, and linkage to care in US prisons, Clinical Infectious Diseases, 70, 1388, 10.1093/cid/ciz383 Austin, 2021, Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma, Journal of Substance Abuse Treatment Bardsley, 2021, The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011–2018, Journal of Viral Hepatitis, 28, 1452, 10.1111/jvh.13575 Bartlett, 2021, Hepatitis C virus prevalence, screening, and treatment among people who are incarcerated in Canada: Leaving no one behind in the direct-acting antiviral era, Clinical Liver Disease, 17, 75, 10.1002/cld.1023 Bartlett, 2021, The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study, Clinical Infectious Diseases Bartlett, 2019, The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals, Liver International, 39, 2261, 10.1111/liv.14227 Biancarelli, 2019, Strategies used by people who inject drugs to avoid stigma in healthcare settings, Drug and Alcohol Dependence, 198, 80, 10.1016/j.drugalcdep.2019.01.037 Biondi, 2020, Hepatitis C models of care: Approaches to elimination, Canadian Liver Journal, 3, 165, 10.3138/canlivj.2019-0002 Brar, 2021, Inability to access primary care clinics among people who inject drugs in a Canadian health care setting, Canadian Family Physician, 67, e348, 10.46747/cfp.6712e348 Bruneau, 2012, The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users, Addiction, 107, 1318, 10.1111/j.1360-0443.2012.03803.x Butler, 2019, Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system, Drug and Alcohol Review, 38, 264, 10.1111/dar.12883 Castro, 2020, Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis, PLoS One, 15, 10.1371/journal.pone.0229143 Chen, 2019, Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings, Journal of Microbiology, Immunology and Infection, 52, 556, 10.1016/j.jmii.2018.10.002 Corcorran, 2021, Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington, Drug and Alcohol Dependence, 220, 10.1016/j.drugalcdep.2021.108525 Cunningham, 2022, Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: A systematic review and meta-analysis, The Lancet Gastroenterology & Hepatology, 7, 426, 10.1016/S2468-1253(21)00471-4 Dalgic, 2019, Improved health outcomes from hepatitis C treatment scale-up in Spain's prisons: A cost-effectiveness study, Scientific Reports, 9, 16849, 10.1038/s41598-019-52564-0 DeBeck, 2017, HIV and the criminalisation of drug use among people who inject drugs: A systematic review, The Lancet HIV, 4, e357, 10.1016/S2352-3018(17)30073-5 Falade-Nwulia, 2020, Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era, Liver International, 40, 2407, 10.1111/liv.14634 Falade-Nwulia, 2017, Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review, Annals of Internal Medicine, 166, 637, 10.7326/M16-2575 Gamkrelidze, 2021, Progress towards hepatitis C virus elimination in high-income countries: An updated analysis, Liver International, 41, 456, 10.1111/liv.14779 Gibbs, 2021, Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system, Drug and Alcohol Dependence, 228, 10.1016/j.drugalcdep.2021.109050 Godin, 2021, The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada, International Journal of Drug Policy, 88, 10.1016/j.drugpo.2020.102738 Grebely, 2017, Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?, Journal of the International AIDS Society, 20, 22146, 10.7448/IAS.20.1.22146 Grebely, 2013, Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels, Journal of Infectious Diseases, 207, S19, 10.1093/infdis/jis928 Grebely, 2020, Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis, Clinical Infectious Diseases, 73, e107, 10.1093/cid/ciaa612 Hajarizadeh, 2018, Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: A systematic review and meta-analysis, The Lancet Gastroenterology & Hepatology, 3, 754, 10.1016/S2468-1253(18)30304-2 Hajarizadeh, 2013, Epidemiology and natural history of HCV infection, Nature Reviews Gastroenterology & Hepatology, 10, 553, 10.1038/nrgastro.2013.107 Hajarizadeh, 2018, Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia, Journal of Viral Hepatitis, 25, 640, 10.1111/jvh.12852 Harris, 2013, Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors, Harm Reduction Journal, 10, 7, 10.1186/1477-7517-10-7 Høj, 2019, Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs, International Journal of Drug Policy, 72, 11, 10.1016/j.drugpo.2019.04.001 2015 Iversen, 2019, Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia, Journal of Hepatology, 70, 33, 10.1016/j.jhep.2018.09.030 Janjua, 2017, Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study, Journal of Viral Hepatitis, 24, 624, 10.1111/jvh.12684 Kronfli, 2021, Disparities in hepatitis C care across Canadian provincial prisons: Implications for hepatitis C micro-elimination, Canadian Liver Journal, 4, 292, 10.3138/canlivj-2020-0035 Kronfli, 2019, The hepatitis C virus cascade of care in a Quebec provincial prison: A retrospective cohort study, CMAJ Open, 7, E674, 10.9778/cmajo.20190068 Latkin, 2017, The relationship between social desirability bias and self-reports of health, substance use, and social network factors among urban substance users in Baltimore, Maryland, Addictive Behaviors, 73, 133, 10.1016/j.addbeh.2017.05.005 Madden, 2018, Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?, PLoS One, 13, 10.1371/journal.pone.0207226 Makarenko, 2019, Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?, International Journal of Drug Policy, 72, 69, 10.1016/j.drugpo.2019.04.002 Marshall, 2020, Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation, International Journal of Drug Policy, 86, 10.1016/j.drugpo.2020.102964 Marshall, 2016, Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study, CMAJ Open, 4, E605, 10.9778/cmajo.20160008 Mendizabal, 2020, Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents, Clinical Gastroenterology and Hepatology, 18, 2554, 10.1016/j.cgh.2020.02.044 Murphy, 2014, CADTH therapeutic reviews Naghdi, 2017, A hepatitis C educational needs assessment of canadian healthcare providers, Canadian Journal of Gastroenterology & Hepatology, 2017, 10.1155/2017/5324290 Nelson, 2011, Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews, The Lancet, 378, 571, 10.1016/S0140-6736(11)61097-0 Oru, 2021, Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: A global systematic review and meta-analysis, The Lancet Global Health, 9, e431, 10.1016/S2214-109X(20)30505-2 Palmateer, 2021, Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: Real-world data, Addiction, 116, 2893, 10.1111/add.15459 Pearce, 2020, Non-disclosure of drug use in outpatient health care settings: Findings from a prospective cohort study in Vancouver, Canada, International Journal of Drug Policy, 84, 10.1016/j.drugpo.2020.102873 Pourmarzi, 2019, Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review, Journal of Viral Hepatitis, 26, 432, 10.1111/jvh.13045 Radley, 2019, A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments, BMC Health Services Research, 19, 765, 10.1186/s12913-019-4635-7 Rojas Rojas, 2019, Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project, International Journal of Drug Policy, 72, 61, 10.1016/j.drugpo.2019.05.013 Saeed, 2019, Eliminating structural barriers: The impact of unrestricted access on hepatitis C treatment uptake amzong people living with human immunodeficiency virus, Clinical Infectious Diseases, 71, 363, 10.1093/cid/ciz833 Schroeder, 2022, It's a revolving door": Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success, International Journal of Drug Policy, 101, 10.1016/j.drugpo.2021.103571 Smith, 2015, Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis, International Journal of Drug Policy, 26, 911, 10.1016/j.drugpo.2015.07.004 Sobell, 1992, 41 Socías, 2019, Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting, Liver International, 39, 1400, 10.1111/liv.14043 The Canadian Network on Hepatitis C Blueprint Writing Committee and Working Group. (2019). Blueprint to inform hepatitis C elimination efforts in Canada. Retrieved from canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf. Thompson, 2016, The influence of gender and other patient characteristics on health care-seeking behaviour: A QUALICOPC study, BMC Family Practice, 17, 38, 10.1186/s12875-016-0440-0 Treloar, 2010, Uptake and delivery of hepatitis C treatment in opiate substitution treatment: Perceptions of clients and health professionals, Journal of Viral Hepatitis, 17, 839, 10.1111/j.1365-2893.2009.01250.x Treloar, 2021, Structural competency in the post-prison period for people who inject drugs: A qualitative case study, International Journal of Drug Policy, 95, 10.1016/j.drugpo.2021.103261 Trooskin, 2020, We must do better: Addressing HCV treatment barriers in persons who inject drugs in the United States, The Journal of Infectious Diseases, 222, S773, 10.1093/infdis/jiaa574 Valerio, 2021, High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia, Journal of Hepatology, 74, 293, 10.1016/j.jhep.2020.08.038 Winter, 2019, Injecting drug use is an independent risk factor for reincarceration after release from prison: A prospective cohort study, Drug and Alcohol Review, 38, 254, 10.1111/dar.12881